{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-221288","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.900588+00:00","generated_at":"2026-06-23T23:58:01.635381+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Inhibikase posts corporate presentation; no specific financial or clinical data in filing","bullets":["Presentation made available on company website on Aug 15, 2022, for investor presentations.","Filing includes only cover page and disclaimer; full slide deck not reproduced in the 8-K.","Presentation is dated 3Q 2022 and focuses on neurodegenerative disease and cancer therapeutics.","No new financial results, guidance, or clinical milestones were disclosed in this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-221288","json":"https://secwatch.observer/filing/0001193125-22-221288.json","markdown":"https://secwatch.observer/filing/0001193125-22-221288.md","text":"https://secwatch.observer/filing/0001193125-22-221288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312522221288/0001193125-22-221288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312522221288/d395011d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:58:01.635381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}